Evidence map›Paper›PMID 29330156›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2018

Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys.

Jeremy C Cornelissen, Samuel Obeng, Kenner C Rice, Yan Zhang, S Stevens Negus, Matthew L Banks

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Effects of selective dopamine D3 receptor partial agonist/antagonists on oxycodone self-administration and antinociception in monkeys.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Medications Development for Treatment of Opioid Use Disorder.Cold Spring Harbor perspectives in medicine · 2021
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jeremy C CornelissenDepartment of Pharmacology and Toxicology, School of Medicine (J.C.C., S.S.N., M.L.B.), and Department of Medicinal Chemistry, School of Pharmacy (S.O., Y.Z.), Virginia Commonwealth University, Richmond, Virginia; and Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.).
Samuel ObengDepartment of Pharmacology and Toxicology, School of Medicine (J.C.C., S.S.N., M.L.B.), and Department of Medicinal Chemistry, School of Pharmacy (S.O., Y.Z.), Virginia Commonwealth University, Richmond, Virginia; and Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.).
Kenner C RiceDepartment of Pharmacology and Toxicology, School of Medicine (J.C.C., S.S.N., M.L.B.), and Department of Medicinal Chemistry, School of Pharmacy (S.O., Y.Z.), Virginia Commonwealth University, Richmond, Virginia; and Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.).
Yan ZhangDepartment of Pharmacology and Toxicology, School of Medicine (J.C.C., S.S.N., M.L.B.), and Department of Medicinal Chemistry, School of Pharmacy (S.O., Y.Z.), Virginia Commonwealth University, Richmond, Virginia; and Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.).
S Stevens NegusDepartment of Pharmacology and Toxicology, School of Medicine (J.C.C., S.S.N., M.L.B.), and Department of Medicinal Chemistry, School of Pharmacy (S.O., Y.Z.), Virginia Commonwealth University, Richmond, Virginia; and Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.).
Matthew L BanksDepartment of Pharmacology and Toxicology, School of Medicine (J.C.C., S.S.N., M.L.B.), and Department of Medicinal Chemistry, School of Pharmacy (S.O., Y.Z.), Virginia Commonwealth University, Richmond, Virginia; and Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.) matthew.banks@vcuhealth.org.
National Institute on Alcohol Abuse and Alcoholism · USNational Institute on Drug Abuse · USVirginia Commonwealth University · US

Funding

Medicinal Chemistry of Drugs Acting on Central and Peripheral Opioid ReceptorsZIADA000527 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI RICE, KENNER · 2009 to 2025
$23.2M
TRAINING IN THE PHARMACOLOGY OF ABUSED DRUGST32DA007027 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI William L. Dewey · 1985 to 2026
$14.7M
Medications Development for Stimulant AbuseR01DA026946 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI NEGUS, SIDNEY S · 2009 to 2019
$3.7M
Non-peptide Mu Opioid Receptor Selective AntagonistsR01DA024022 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ZHANG, YAN · 2009 to 2019
$3.5M
Bivalent Ligands as Chemical Probes to Study Opioid Abuse-enhanced HIV InfectionR01DA044855 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F, ZHANG, YAN · 2017 to 2021
$2.7M
Behavioral effects of NMDA antagonist/opioid agonist combinationsR01DA037287 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI BANKS, MATTHEW L, NICHOLSON, KATHERINE L · 2014 to 2018
$2.0M
NIDA NIH HHS R01 DA024022NIDA NIH HHS R01 DA026946NIDA NIH HHS R01 DA037287NIDA NIH HHS R01 DA044855NIDA NIH HHS T32 DA007027
6 · The paper itself

Abstract

Receptor theory predicts that fixed-proportion mixtures of a competitive, reversible agonist (e.g., fentanyl) and antagonist (e.g., naltrexone) at a common receptor [e.g., mu-opioid receptors (MORs)] will result in antagonist proportion-dependent decreases in apparent efficacy of the agonist/antagonist mixtures and downward shifts in mixture dose-effect functions. The present study tested this hypothesis by evaluating behavioral effects of fixed-proportion fentanyl/naltrexone mixtures in a warm-water tail-withdrawal procedure in rhesus monkeys (

Indexed as

Drug DesignAnimalsDose-Response Relationship, DrugDrug InteractionsFentanylLigandsMacaca mulattaMaleModels, StatisticalNaltrexoneReceptors, Opioid, muFentanylLigandsNaltrexoneReceptors, Opioid, mu

Identifiers

PMID29330156
PMCPMC5830633
OpenAlexW2783897324

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.